Citable filing context
IQV's research view summarizes recent SEC filing context, starting with earnings from Jul 28, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 28, 2026 | earnings | IQVIA reported second-quarter 2026 revenue of $4.368 billion, up 8.7% year-over-year, and raised its full-year 2026 guidance. |
| Jun 11, 2026 | debt_offering | IQVIA Inc. issued €950 million in 4.625% senior notes due 2033 to refinance existing indebtedness. |
| Jun 4, 2026 | debt_offering | IQVIA priced an offering of €950 million in aggregate principal amount of senior notes due 2033. |
| Jul 28, 2026 | Guidance: adjusted_diluted_eps | 12.80 to 13.00 |
| Jul 28, 2026 | Guidance: adjusted_ebitda | 4000.00 to 4050.00 |
| Jul 28, 2026 | Guidance: revenue | 17275.00 to 17475.00 |
| Jul 28, 2026 | mda_quarterly | IQVIA reported strong financial performance for the first half of 2026, with total revenues reaching $8.52 billion, an 8.6% increase over the prior-year period. Growth was driven by both reportable segments: Commercial Solutions, which grew 10.1% to $3.55 billion, and Research & Development Solutions, which rose 7.5% to $4.97 billion. The R&D segment remains a primary revenue driver, supported by a robust contracted backlog of $34.2 billion, of which $9.2 billion is expected to convert to revenue within the next twelve months. Effective January 1, 2026, the company reorganized its reporting structure, consolidating Contract Sales & Medical Solutions into the renamed Commercial Solutions segment and shifting certain Real-World offerings into the R&D segment. Operating expenses rose due to higher compensation costs and increased restructuring efforts aimed at streamlining global operations. Liquidity remains stable with $1.91 billion in cash and cash equivalents. During the first half of 2026, IQVIA issued €950 million in 4.625% senior notes due 2033 to refinance debt, including a 364-day term loan. The company continues to prioritize shareholder returns, repurchasing $950 million of common stock and increasing its total repurchase authorization to $15.73 billion. Management remains in compliance with all material debt covenants. |
| May 5, 2026 | mda_quarterly | IQVIA reported total revenues of $4.15 billion for the first quarter of 2026, an 8.4% increase over the same period in 2025. This growth was driven by a 6.0% increase in constant currency revenue, with Commercial Solutions contributing $1.75 billion and Research & Development Solutions contributing $2.40 billion. The company recently reorganized its reporting structure, consolidating Contract Sales & Medical Solutions into the renamed Commercial Solutions segment and shifting certain Real-World offerings into the Research & Development Solutions segment. Operating performance remains robust, with income from operations rising to $514 million from $496 million in the prior year. The Research & Development Solutions segment maintains a strong contracted backlog of $34.2 billion, with approximately $8.9 billion expected to convert to revenue within the next twelve months. Liquidity remains stable, with $1.95 billion in cash and cash equivalents. During the quarter, IQVIA utilized a new $650 million Term Loan due 2027 to retire €550 million of 1.750% senior notes. The company continues to execute its capital allocation strategy, repurchasing $552 million of common stock during the quarter. Management expects ongoing restructuring efforts to continue through 2027 to streamline operations and integrate recent acquisitions. |
Source: SEC EDGAR filing text and events; period Jul 28, 2026; filed Jul 28, 2026.
IQV company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.